Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

August 9, 2006

Primary Completion Date

May 22, 2012

Study Completion Date

October 10, 2014

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

Rituximab

On days 1, 8, 15 and 22 of the 1st cycle, bortezomib will be administered intravenously (through a vein) over 3-5 seconds followed by an intravenous infusion of rituximab. How long it will take to infuse the dose of rituximab is dependent upon your weight and how well you tolerate the infusion; it is estimated this first infusion may take between 3-4 hours. During subsequent cycles, bortezomib will again be given on days 1, 8, 15 and 22. However, rituximab will only be given on day 1 of each cycle.

DRUG

bortezomib

On days 1, 8, 15 and 22 of the 1st cycle, bortezomib will be administered intravenously (through a vein) over 3-5 seconds followed by an intravenous infusion of rituximab. How long it will take to infuse the dose of rituximab is dependent upon your weight and how well you tolerate the infusion; it is estimated this first infusion may take between 3-4 hours. During subsequent cycles, bortezomib will again be given on days 1, 8, 15 and 22. However, rituximab will only be given on day 1 of each cycle.

Trial Locations (4)

33136

University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami

60611

Northwestern University, Chicago

60611-2998

Hematology-Oncology Associates of Illinois, Chicago

19111-2497

Fox Chase Cancer Center - Philadelphia, Philadelphia

All Listed Sponsors
collaborator

Robert H. Lurie Cancer Center

OTHER

lead

Northwestern University

OTHER

NCT00369707 - Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL | Biotech Hunter | Biotech Hunter